Industry News

Johnson & Johnson (J&J) has announced a proposed 5.5 billion USD settlement aimed at resolving nearly all remaining U.S. lawsuits alleging that its talc-based products caused ovarian cancer, marking one of the largest mass-tort settlement efforts in the company's history. The proposed agreement covers approximately 76,000 pending claims and will take effect only if at least 95% of eligible claimants agree to participate.

Akums Drugs & Pharmaceuticals Ltd., India's leading Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of Oriflame India's manufacturing business, marking its entry into the fast-growing color cosmetics manufacturing sector while significantly expanding its personal care and wellness portfolio.

Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Susvimo® (ranibizumab) for the treatment of neovascular age-related macular degeneration (nAMD). If the European Commission grants final approval, Susvimo will become the first continuous drug-delivery treatment for nAMD in the European Union.

The U.S. Food and Drug Administration (US FDA) has issued a Warning Letter to Almon Healthcare Private Limited, Ahmedabad, Gujarat, after identifying significant violations of Current Good Manufacturing Practice (CGMP) regulations at its active pharmaceutical ingredient (API) manufacturing facility during an inspection conducted from February 9–13, 2026. The warning letter was issued on July 13, 2026.

Novo Nordisk has announced that it has filed a lawsuit against Eli Lilly and Company in the United States, alleging that Lilly's advertising campaigns for its GLP-1 medicines are misleading and do not present complete scientific information.

Global pharmaceutical company Sanofi has received a Public Reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) after a complaint was filed by Pfizer.

The PMCPA investigated the case (CASE/0689/08/25) and found that Sanofi had breached several rules of the 2024 ABPI Code of Practice, which sets standards for how pharmaceutical companies should promote their medicines in the UK.

Cipla Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Central Islip, Long Island, New York, USA.

The inspection was carried out from July 13 to July 17, 2026 (EDT) as part of the USFDA's routine regulatory oversight of pharmaceutical manufacturing facilities.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

Alembic Pharmaceuticals Limited (Alembic) today announced that its Partner NATCO Pharma Limited (NATCO) has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Olaparib Tablets, 100 mg and 150 mg. 

In a landmark development for dengue prevention, the Drug Controller General of India (DCGI) has granted market authorization to Takeda Biopharmaceuticals India's QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]), making it the first dengue vaccine approved in India. The vaccine is approved for the prevention of dengue in individuals 4 to 60 years of age and can be administered regardless of prior dengue infection, eliminating the need for pre-vaccination screening.